Entrectinib granted priority review for ROS1 NSCLC and NTRK solid tumors

Yesterday the FDA has granted Priority Review for entrectinib for the treatment of ROS1-positive NSCLC and NTRK fusion-positive solid tumors. The FDA is expected to make a decision on approval by August 18, 2019.

FDA Grants Priority Review to Genentech’s Personalized Medicine Entrectinib

Published by

Gray Connections

I was diagnosed with non-small cell lung cancer in May 2011. The cancer became metastatic in October 2011. No, I never smoked anything (except a salmon). I've had no evidence of disease since January 2013 thanks to precision medicine, clinical trials, and other patients. ANYONE can get lung cancer. Using my engineering degrees (MIT SBME 1978, Caltech Aeronautics MS 1984 and ENGR 1986), I enjoyed a 20-year career in aerospace systems engineering as a technical translator of sorts: I researched a scientific or engineering subject and helped others understand how this new gizmo could benefit them. In the time I have left, I want to use my skills to help others who have lung cancer, and increase the visibility and knowledge of lung cancer among those who don't. I also study brain research, enjoy traveling, write science fiction, and geek out about all sorts of science stuff.